reasons to choose taiwan ubi asia in partnership with ubi chang yi wang, phd founder, ubi...

Click here to load reader

Post on 26-Dec-2015

239 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • Slide 1
  • Reasons to Choose Taiwan UBI Asia in Partnership with UBI Chang Yi Wang, PhD Founder, UBI Chairperson, UBI Asia
  • Slide 2
  • Functional Antigenics UBI / UBI Asia Molecular Design of Functional Antigens Adjuvant & Formulation Technologies UBITh Technology Synthetic Peptide Technologies Antigenic Combinatorial Library Cytotoxic T Lymphocyte Neutralization Antibodies Vaccines and Immunotherapeutics Immunodiagnostics Therapeutic Monoclonal Antibodies Antibody Deimmunization Core Technology
  • Slide 3
  • Vaccines & Immunotherapeutics Animal Health Products Human Health Products Functional Antigenics Canine Allergy Therapeutic FMDV Vaccine & Diagnostics LHRH Vaccine for Boar Taint Removal & Growth Promotion LHRH Vaccine as Pet Contraceptive LHRH Vaccine as Prostate Cancer Therapeutic HIV/AIDS Vaccine & Therapeutic Allergy Therapeutic Alzheimer Disease Therapeutic SARS Vaccine & Diagnostics Product Portfolios
  • Slide 4
  • Division of AIDS, NIAID, NIH, USA [HIV Immunotherapeutics] NIAID, NIH, USA [Allergy Immunotherapeutic] NCI, NIH, USA [Prostate Cancer Immunotherapeutic] Baxter, USA BioMerieux (Lyon, France), formerly Organon Teknika of Akzo Nobel (Boxtel, Netherlands) Merial (Lyon, France) (JV of Merck and Aventis, largest animal health company in the world) The United Laboratories (Zhuhai, China) China Animal Husbandry Industry Corp. (Beijing, China) Business partners and Product Development Sponsors of UBI
  • Slide 5
  • Synergy: Traditional Pharma / Innovative Bio Peptide Pilot Plant Protein Drug Pilot Plant Biologics Manufacture Plant cGMP Roche GSK BioPharmaceutics Foundation in Taiwan Toll Manufacture Pharmaceutics Foundation in Taiwan Compliance with FDA International BioPharmaceutics Company Specialty Injectables
  • Slide 6
  • rowth Survival cGMP Pharmaceutical Plants Synergy Pharma / Bio Synergy UBI / UBI Asia Business Model
  • Slide 7
  • UBI UBI Asia & Survival: Conservative Nurtures High RiskcGMPManufacture Acquire Roche & GSK cGMP plants:Acquire Roche & GSK cGMP plants: Chemical drugs, Biologics Chemical drugs, Biologics 19992002 Innovative R & D Peptide based:Peptide based: Vaccine & diagnostics Protein based:Protein based: Therapeutic monoclonal antibodies
  • Slide 8
  • FMDV Vaccine: Ko-T Con FMDV Diagnostics From Genomics to Products Innovation Through Design UBI Asia
  • Slide 9
  • The Vision: Complete Replacement of Traditional Vaccines within 5 Years !!
  • Slide 10
  • UBITh LHRH Immunotherapeutic Boar Taint Removal Vaccine: Bota Con Pet Contraceptive Vaccine Human Prostate Cancer Therapeutic From Genomics to Products Innovation Through Design UBI Asia
  • Slide 11
  • BotaCon : An Immunotherapeutic to eliminate Boar Taint and promote pig growth and
  • Slide 12
  • Cattle
  • Slide 13
  • Therapeutic Monoclonal Antibodies UBI Asia
  • Slide 14
  • Monoclonal Antibody Humanization (Murine Ab to Human Ab) Hybridoma, Cesar Milstein & Georges Kohler Chimeric mAb, Genentech Fc Fv CDR grafting, PDL 1975 19941986 OKT3, 1986, 55 M USD RePro, 1994, 447 M USDRituxan, 1997, 298 M USD Deimmunization, Biovation 1998 Identification of T cell and B cell antigenic epitopes in Variable regions Monoclonal Antibody Engineering
  • Slide 15
  • Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for treatment of HARRT resistant AIDS patients through entry inhibition Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for treatment of HARRT resistant AIDS patients through entry inhibition
  • Slide 16
  • & UBI Asia R & D UBI Asia provides services to and collaborates with multiple commercial and research institutes cGMP &
  • Slide 17
  • UBI & UBI Asia & Vision: Designer Immunological Products for the treatment, prevention, and diagnosis of globally significant diseases
  • Slide 18
  • Synergy: UBI Asia / UBI UBI Asia R & D Center Basic Research Process Development Field & Clinical Trials UBI MOEANIH
  • Slide 19
  • Reasons to Choose Taiwan UBI Asia in Partnership with UBI Taiwan government with policies to promote biotechnology Taiwan has diligent, entrepreneurial and well-educated human resources Operations can be cost effective when compared with the west Easy access to fast breaking first hand business information Access to huge China market due to similarity in language and cultural background Training and testing ground for worldmarket due to its extensive connections to the western world
  • Slide 20
  • Join us, and Welcome to Taiwan!